Merck &’s (MRK) Outperform Rating Reaffirmed at BMO Capital Markets

Merck & Company, Inc. (NYSE:MRK)‘s stock had its “outperform” rating reissued by BMO Capital Markets in a research note issued to investors on Thursday. They presently have a $72.00 price objective on the stock. BMO Capital Markets’ target price points to a potential upside of 12.89% from the company’s current price.

Other research analysts also recently issued research reports about the company. UBS AG raised their price target on Merck & from $70.00 to $72.00 and gave the stock a “buy” rating in a research note on Monday, July 31st. Piper Jaffray Companies set a $70.00 price target on Merck & and gave the stock a “buy” rating in a research note on Saturday, July 29th. Zacks Investment Research downgraded Merck & from a “buy” rating to a “hold” rating in a research note on Wednesday, August 2nd. BidaskClub upgraded Merck & from a “sell” rating to a “hold” rating in a research note on Tuesday, August 1st. Finally, HSBC Holdings plc upgraded Merck & from a “reduce” rating to a “hold” rating in a research note on Wednesday, August 9th. Three research analysts have rated the stock with a sell rating, seven have given a hold rating and twelve have given a buy rating to the company. Merck & currently has an average rating of “Hold” and a consensus target price of $69.81.

Shares of Merck & (MRK) traded down 0.149% during midday trading on Thursday, hitting $63.685. The stock had a trading volume of 969,996 shares. The firm has a 50 day moving average price of $64.46 and a 200 day moving average price of $63.70. Merck & has a one year low of $58.29 and a one year high of $66.80. The stock has a market cap of $173.69 billion, a PE ratio of 34.480 and a beta of 0.80.

Merck & (NYSE:MRK) last released its quarterly earnings results on Friday, July 28th. The company reported $1.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.87 by $0.14. The firm had revenue of $9.93 billion for the quarter, compared to the consensus estimate of $9.75 billion. Merck & had a return on equity of 26.02% and a net margin of 17.14%. The firm’s quarterly revenue was up .9% compared to the same quarter last year. During the same quarter last year, the business posted $0.93 EPS. On average, equities analysts forecast that Merck & will post $3.87 earnings per share for the current fiscal year.

WARNING: This article was originally reported by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this article on another publication, it was illegally copied and republished in violation of US & international copyright & trademark law. The original version of this article can be viewed at https://sportsperspectives.com/2017/10/12/merck-s-mrk-outperform-rating-reaffirmed-at-bmo-capital-markets.html.

Several institutional investors and hedge funds have recently bought and sold shares of MRK. Bollard Group LLC lifted its holdings in shares of Merck & by 6.3% in the 1st quarter. Bollard Group LLC now owns 86,237 shares of the company’s stock valued at $5,479,000 after buying an additional 5,110 shares during the period. Boys Arnold & Co. Inc. lifted its holdings in shares of Merck & by 1.0% in the 1st quarter. Boys Arnold & Co. Inc. now owns 62,180 shares of the company’s stock valued at $3,951,000 after buying an additional 605 shares during the period. Columbus Circle Investors lifted its holdings in shares of Merck & by 529.0% in the 1st quarter. Columbus Circle Investors now owns 1,345,334 shares of the company’s stock valued at $85,483,000 after buying an additional 1,131,452 shares during the period. Hengehold Capital Management LLC lifted its holdings in shares of Merck & by 2.8% in the 1st quarter. Hengehold Capital Management LLC now owns 30,877 shares of the company’s stock valued at $1,962,000 after buying an additional 850 shares during the period. Finally, Sabal Trust CO lifted its holdings in shares of Merck & by 76.7% in the 1st quarter. Sabal Trust CO now owns 12,165 shares of the company’s stock valued at $773,000 after buying an additional 5,281 shares during the period. 72.91% of the stock is owned by institutional investors and hedge funds.

Merck & Company Profile

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Analyst Recommendations for Merck & (NYSE:MRK)

Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply